Trevi Therapeutics, Inc.
TRVI
$14.76
-$0.12-0.81%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -58.63% | 29.54% | 4.06% | -18.97% | 9.42% |
| Total Depreciation and Amortization | 9.68% | -18.42% | 0.00% | 2.70% | -2.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 106.76% | -14.34% | -5.22% | 20.11% | 13.08% |
| Change in Net Operating Assets | -1,869.34% | -62.13% | -116.08% | 125.64% | -506.24% |
| Cash from Operations | -118.70% | 29.86% | -7.71% | 25.05% | -41.12% |
| Capital Expenditure | -- | 100.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 155.76% | 39.90% | -1,851.19% | 73.77% | 58.30% |
| Cash from Investing | 155.43% | 39.91% | -1,851.65% | 73.77% | 58.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | 64.52% |
| Issuance of Common Stock | -21.83% | -74.71% | -98.99% | 1,139.24% | -82.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | 237.50% | -65.77% | -- |
| Cash from Financing | -21.83% | -82.57% | -98.52% | 1,168.18% | -83.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 101.31% | 36.94% | -161.62% | 763.48% | -181.59% |